Shilpa Iyer1,2, Katharina Laus3, Angela Rugino3, Carolyn Botros4, Svjetlana Lozo4, Sylvia M Botros5, Roger Goldberg4, Janet Tomezsko6, Adam Gafni-Kane4, Kristen Wroblewski7, Peter Sand4. 1. Department of Obstetrics and Gynecology, Section of Urogynecology, The University of Chicago, Chicago, IL, USA. Siyer2@bsd.uchicago.edu. 2. Department of Obstetrics and Gynecology, Gynecology and Reconstructive Pelvic Surgery, The University of Chicago, 5841 South Maryland Avenue, MC 2050, Chicago, IL, 60637-1470, USA. Siyer2@bsd.uchicago.edu. 3. Department of Obstetrics and Gynecology, Section of Urogynecology, The University of Chicago, Chicago, IL, USA. 4. Department of Obstetrics and Gynecology, Section of Urogynecology, Center for Pelvic Health, North Shore University Health System, affiliated with The University of Chicago, Skokie, IL, USA. 5. Department of Urology, The University of Texas at San Antonio, San Antonio, TX, USA. 6. Womens Health Institute of Illinois, Skokie, IL, USA. 7. Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA.
Abstract
INTRODUCTION AND HYPOTHESIS: We investigated the objective improvements in overactive bladder (OAB) symptoms in patients undergoing percutaneous tibial nerve stimulation (PTNS) and predictive factors of patient satisfaction. METHODS: In this single-center retrospective cohort study at a tertiary urogynecology center, we identified all female patients who underwent PTNS therapy from 1 October 2007 - 1 January 2016 and followed them from their initial visit through medication therapy and PTNS treatments. Patients who tried at least one medication prior to starting PTNS therapy and completed at least one PTNS visit were included. Baseline demographic data, urinary data, and details of medication and PTNS therapy sessions were collected from records through chart review. Paired or two-sample t-tests were used to compare changes over time or groups. Bivariate and multivariable logistic regression were performed. RESULTS: Two hundred thirteen patients underwent PTNS therapy and 183 patients met the criteria. Overall patients were able to decrease voiding frequency by 1 h, decrease nocturia episodes by 0.8, and decrease urge incontinence episodes with PTNS therapy by ten episodes per week (p = 0.02). Patients who continued OAB medications did not have additional improvements compared with patients who did not continue OAB medications during PTNS. Overall, 25.4% (43/169) patients reported ≥ 75% improvement during PTNS therapy, and 61.5% (104/169) reported ≥ 50% improvement. When evaluating predictive factors of ≥ 50% overall improvement, the number of PTNS sessions increased odds of subjective success (OR = 1.8, p = 0.004). Other factors were not significant predictors of subjective PTNS success. CONCLUSIONS: PTNS can provide both objective and subjective improvements for patients who do not respond to OAB medication therapy.
INTRODUCTION AND HYPOTHESIS: We investigated the objective improvements in overactive bladder (OAB) symptoms in patients undergoing percutaneous tibial nerve stimulation (PTNS) and predictive factors of patient satisfaction. METHODS: In this single-center retrospective cohort study at a tertiary urogynecology center, we identified all female patients who underwent PTNS therapy from 1 October 2007 - 1 January 2016 and followed them from their initial visit through medication therapy and PTNS treatments. Patients who tried at least one medication prior to starting PTNS therapy and completed at least one PTNS visit were included. Baseline demographic data, urinary data, and details of medication and PTNS therapy sessions were collected from records through chart review. Paired or two-sample t-tests were used to compare changes over time or groups. Bivariate and multivariable logistic regression were performed. RESULTS: Two hundred thirteen patients underwent PTNS therapy and 183 patients met the criteria. Overall patients were able to decrease voiding frequency by 1 h, decrease nocturia episodes by 0.8, and decrease urge incontinence episodes with PTNS therapy by ten episodes per week (p = 0.02). Patients who continued OAB medications did not have additional improvements compared with patients who did not continue OAB medications during PTNS. Overall, 25.4% (43/169) patients reported ≥ 75% improvement during PTNS therapy, and 61.5% (104/169) reported ≥ 50% improvement. When evaluating predictive factors of ≥ 50% overall improvement, the number of PTNS sessions increased odds of subjective success (OR = 1.8, p = 0.004). Other factors were not significant predictors of subjective PTNS success. CONCLUSIONS:PTNS can provide both objective and subjective improvements for patients who do not respond to OAB medication therapy.
Authors: Kenneth M Peters; Donna J Carrico; Ramon A Perez-Marrero; Ansar U Khan; Leslie S Wooldridge; Gregory L Davis; Scott A Macdiarmid Journal: J Urol Date: 2010-02-20 Impact factor: 7.450
Authors: Kenneth M Peters; Scott A Macdiarmid; Leslie S Wooldridge; Fah Che Leong; S Abbas Shobeiri; Eric S Rovner; Steven W Siegel; Susan B Tate; Barry K Jarnagin; Peter L Rosenblatt; Brian A Feagins Journal: J Urol Date: 2009-07-18 Impact factor: 7.450
Authors: Alexis M Tran; Renata Reis; Shilpa Iyer; Carolyn Botros; Roger P Goldberg; Peter K Sand; Sylvia M Botros Journal: Female Pelvic Med Reconstr Surg Date: 2018 May/Jun Impact factor: 2.091
Authors: E Finazzi Agrò; A Campagna; F Sciobica; F Petta; S Germani; A Zuccalà; R Miano Journal: Minerva Urol Nefrol Date: 2005-06 Impact factor: 3.720
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226